BridgeBio Pharma, Inc.

Listed Company

BBIOCIK 0001743881NasdaqLarge AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$502.08M

Net Income

$-732.94M

Total Assets

$936.02M

Equity

$-2.09B

Shares Out

195.86M

Op. Cash Flow

$-445.91M

BBIO$81.39+74.10% · past yearDBEQ Basic

Daily closing prices

Business

BridgeBio Pharma, Inc. is a biopharmaceutical company that discovers, develops and commercializes targeted therapies for patients with genetic diseases. Its main products and candidates include the approved TTR stabilizer acoramidis (marketed as Attruby/Beyonttra) and clinical-stage programs such as low-dose infigratinib, encaleret and BBP-418, alongside earlier-stage discovery programs supported by its product platform. The company operates through research and development, commercial operations and subsidiary affiliates (including entities focused on specific programs) and relies on third-party contract manufacturers. It sells in the United States through a direct commercial organization and distributes via specialty pharmacies, specialty distributors and 3PL providers while partnering with regional companies for Europe, Japan and other territories.

Summary from filing dated 2025-02-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues, net	502	222	9	78	70
Total cost of revenues	21	4	2	3	3
Research and development	452	506	456	399	451
Selling, general and administrative	531	289	151	143	192
Restructuring, impairment, and related charges	21	16	8	—	—
Total operating costs and expenses	1,025	815	617	590	646
Loss from operations	−523	−593	−607	−512	−577
Interest income	20	17	18	8	1
Interest expense	−53	−91	−81	−80	—
Noncash interest expense on deferred royalty obligations	−125	−8	0	—	—
Gain on deconsolidation of subsidiaries	0	178	0	0	—
Loss on extinguishments of debt	−21	−27	0	0	—
Net loss from equity method investments	−73	−31	0	0	—
Other income, net	43	12	17	−8	36
Total other income (expense), net	−209	51	−46	28	−10
Loss before income taxes	−733	−542	−653	−485	—
Provision for income taxes	435,000	1	0	0	—
Net loss	−733	−543	−653	−485	−586
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests	8	8	10	3	24
Net loss attributable to common stockholders of BridgeBio	−725	−536	−643	−481	−563
Net loss per share attributable to common stockholders of BridgeBio, basic (in dollars per share)	−3.78	−2.88	−3.95	−3.26	−3.9
Net loss per share attributable to common stockholders of BridgeBio, diluted (in dollars per share)	−3.78	−2.88	−3.95	−3.26	−3.9
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic (in shares)	192	186	163	147	144
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted (in shares)	192	186	163	147	144

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	570	681	376	377	394
Marketable securities	17	0	—	—	—
Accounts receivable, net	139	5	2	—	—
Inventories	27	0	—	—	—
Prepaid expenses and other current assets	44	35	24	22	32
Total current assets	798	721	478	549	889
Equity method investments	80	144	—	—	—
Property and equipment, net	5	7	12	15	30
Operating lease right-of-use assets	8	6	8	11	16
Intangible assets, net	28	24	26	29	45
Other assets	17	18	23	20	33
Total assets	936	919	546	623	1,013
Accounts payable	36	10	11	12	12
Accrued compensation and benefits	77	58	57	31	37
Accrued research and development liabilities	41	34	30	40	44
Operating lease liabilities, current portion	6	5	4	4	5
Deferred revenue, current portion	7	15	—	—	—
Other current liabilities	120	33	—	—	—
Total current liabilities	288	154	144	121	135
Deferred royalty obligations, net	855	479	0	—	—
Operating lease liabilities, net of current portion	4	5	9	12	17
Deferred revenue, net of current portion	13	17	—	—	—
Other long-term liabilities	244,000	286,000	6	27	22
Total liabilities	3,013	2,377	1,889	1,868	1,878
Commitments and contingencies (Note 8)	—	—	—	—	—
Redeemable convertible noncontrolling interests	−570,000	142,000	478,000	−2	1
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding	0	0	—	—	—
Common stock, $0.001 par value; 500,000,000 shares authorized; 198,759,831 shares issued and 192,633,286 shares outstanding as of December 31, 2025, 196,236,234 shares issued and 190,044,473 shares outstanding as of December 31, 2024	202,000	196,000	181,000	157,000	154,000
Treasury stock, at cost; 7,597,172 shares as of December 31, 2025; 6,191,761 shares as of December 31, 2024	−323	−275	—	—	—
Additional paid-in capital	2,058	1,903	—	—	—
Accumulated other comprehensive income	12,000	8,000	31,000	−328,000	−132,000
Accumulated deficit	−3,821	−3,096	−2,561	−1,918	−1,437
Total BridgeBio stockholders deficit	−2,087	−1,468	−1,354	−1,255	−870
Noncontrolling interests	11	10	11	11	3
Total stockholders deficit	−2,076	−1,458	−1,343	−1,243	−867
Total liabilities, redeemable convertible noncontrolling interests and stockholders deficit	936	919	546	623	1,013

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	133	96	109	92	100
Amortization of debt discount and issuance costs	6	7	9	—	—
Depreciation and amortization	5	6	6	7	6
Noncash lease expense	5	4	4	—	—
Change in fair value of the embedded derivative associated with the deferred royalty obligation	−20	−2	0	—	—
Noncash income from equity method investments	−9	0	0	—	—
(Gain) loss on deconsolidation of subsidiaries	0	−178	1	—	—
Gain from investment in equity securities, net	0	−8	−18	8	−30
Accrual of payment-in-kind interest on term loan	0	0	10	—	—
Other noncash adjustments, net	−2	−935,000	−803,000	2	7
Accounts receivable, net	−135	−3	15	15	—
Inventories	−25	0	0	—	—
Prepaid expenses and other current assets	−9	−14	−3	8	−4
Other assets	1	2	−2	11	−10
Accounts payable	27	2	3	−349,000	3
Accrued compensation and benefits	23	17	8	−2	7
Accrued research and development liabilities	7	9	−10	−4	11
Operating lease liabilities	−7	−6	−5	−6	−6
Deferred revenue	−11	22	−5	15	0
Other liabilities	78	4	4	—	—
Net cash used in operating activities	−446	−521	−528	−419	−498
Purchases of marketable securities	−28	−94	−30	—	—
Maturities of marketable securities	11	95	83	—	—
Purchases of investments in equity securities	0	−20	−108	−56	−53
Proceeds from sales of investments in equity securities	0	63	111	53	34
Proceeds from special cash dividends received from an investment in equity securities	2	26	0	0	—
Payment for intangible assets	−8	−8	0	−2	−35
Purchases of property and equipment	−1	−933,000	−1	−5	−13
Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries	0	−140,000	−503,000	—	—
Net cash provided by (used in) investing activities	−24	61	54	453	−201
Repurchase of common stock	−48	0	0	0	−200
Repayment of term loans	−459	−473	0	—	—
Repayments of deferred royalty obligations	−15	0	0	—	—
Proceeds from issuance of common stock through public offerings, net	0	315	450	5	0
Proceeds from common stock issuances under ESPP	6	5	3	3	4
Proceeds from stock option exercises, net of repurchases	28	4	6	666,000	17
Transactions with noncontrolling interests	2	0	−801,000	—	—
Repurchase of RSU shares to satisfy tax withholding	−14	−8	−7	−2	−5
Net cash provided by financing activities	359	748	452	−13	736
Net increase (decrease) in cash, cash equivalents, and restricted cash	−111	289	−22	21	38
Cash paid for interest	44	91	61	54	30
Cash paid for income taxes	1	0	0	—	—
Unpaid property and equipment	43,000	279,000	100,000	47,000	563,000
Transfers to noncontrolling interests	−6	−6	−11	−4	−2

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is BridgeBio Pharma, Inc.'s CIK number?

BridgeBio Pharma, Inc.'s SEC CIK number is 0001743881 (1743881). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find BridgeBio Pharma, Inc.'s SEC filings?

All of BridgeBio Pharma, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did BridgeBio Pharma, Inc. last report earnings?

BridgeBio Pharma, Inc. (BBIO) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001743881-26-000018). This is BridgeBio Pharma, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is BridgeBio Pharma, Inc.'s most recent earnings 8-K?

BridgeBio Pharma, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001743881-26-000018. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View BridgeBio Pharma, Inc.'s latest earnings 8-K →
Look up any company's CIK number →